BELLEROPHON THERAPEUTICS INC (BLPH) Forecast, Price Target & Analyst Ratings

NASDAQ:BLPH • US0787713009

Current stock price

0.1025 USD
-0.28 (-73.39%)
At close:
0.114 USD
+0.01 (+11.22%)
After Hours:

Analyst forecast overview

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for BELLEROPHON THERAPEUTICS INC (BLPH).

Forecast Snapshot

Consensus Price Target

Price Target
$2.04
+ 1,890.24% Upside
→ Price target details

Next Earnings Forecast

Earnings Estimate
Release Date
Nov 13, 2023
Period
Q3 / 2023
EPS Estimate
-$0.45
Revenue Estimate
→ Full earnings forecast details

ChartMill Buy Consensus

Rating
43.33%
Weighted Analyst Rating Score
→ Analyst Ratings details

Price Target Details & History

Consensus Price Target and Range

Mean target
$2.04
Upside
+ 1,890.24%
From current price of $0.10 to mean target of $2.04, Based on 6 analyst forecasts
Low
$2.02
Median
$2.04
High
$2.10

Price Target Revisions

1 Month
0.00%
3 Months
0.00%

Price Target Summary

6 Wall Street analysts provided a forecast for the next 12 months for BLPH. The average price target is 2.04 USD. This implies a price increase of 1890.24% is expected in the next year compared to the current price of 0.1025.
→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

BLPH Current Analyst RatingBLPH Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 0.5 1 1.5 2 2.5

Analyst Ratings History

BLPH Historical Analyst RatingsBLPH Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -19 -17 -15 -13 -11 -9 -7 -5 -3 -1 2 4 6 8

Analyst Ratings Consensus

ChartMill Buy Consensus
43.33%
BLPH was analyzed by 6 analysts. The buy percentage consensus is at 43. So analysts seem to be rather negative about BLPH.
In the previous month the buy percentage consensus was at a similar level.
BLPH was analyzed by 6 analysts. More opinions would make the average more meaningful.
→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

DateFirmActionFrom → To
2023-06-06Laidlaw & Co.Downgrade Buy -> Hold
2023-06-06HC Wainwright & Co.Maintains Buy -> Buy
2023-05-17HC Wainwright & Co.Reiterate Buy -> Buy
2023-05-09Laidlaw & Co.Initiate Buy
2023-04-04HC Wainwright & Co.Reiterate Buy

Next Earnings Forecast Details

Next Earnings Details

Release Date
Nov 13, 2023
Period
Q3 / 2023
EPS Estimate
-$0.45
Revenue Estimate
Revenue Q2Q
N/A
EPS Q2Q
15.32%
Number of Analysts
3

Next Earnings Revisions

Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
0.00%
EPS (3 Months)
-3.53%

Next Earnings Summary

BLPH is expected to report earnings on 11/13/2023. The consensus EPS estimate for the next earnings is -0.45 USD and the consensus revenue estimate is 0 USD.
→ Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates 2023 - 2030

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030
Revenue
YoY % growth
BLPH revenue by date.BLPH revenue by date.
N/AN/A
-100.00%		N/AN/A
-30.68%		N/A
96.52%		N/A
56.17%		N/A
27.30%		N/A
16.40%
EBITDA
YoY % growth
BLPH ebitda by date.BLPH ebitda by date.
-47.86M-23.36M
51.19%		-24.23M
-3.72%		-27.52M
-13.58%		-17.12M
37.79%		-26.13M
-52.63%		-20.059M
23.23%		-22.319M
-11.27%		N/AN/AN/AN/AN/AN/AN/AN/A
EBIT
YoY % growth
BLPH ebit by date.BLPH ebit by date.
-48.24M-23.76M
50.75%		-24.6M
-3.54%		-27.88M
-13.33%		-17.47M
37.34%		-26.28M
-50.43%		-20.161M
23.28%		-22.384M
-11.03%		N/A
45.42%		N/A
-65.46%		N/A
329.80%		N/A
-79.29%		N/A
237.63%		N/A
59.64%		N/A
29.63%		N/A
10.78%
Operating Margin
BLPH operating margin by date.BLPH operating margin by date.
N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
EPS
YoY % growth
BLPH eps by date.BLPH eps by date.
-57.75-23.85
58.70%		N/A-4.50-2.95
34.44%		-3.29
-11.53%		-1.88
42.86%		-2.08
-10.64%		N/A
50.96%		N/A
-82.00%		N/A
180.77%		N/A
-66.67%		N/A
232.65%		N/A
58.28%		N/A
28.29%		N/A
9.67%

All data in USD

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

Q3 / 23 Q4 / 23
EPS
Q2Q % growth		-0.45
15.32%		-0.43
19.17%
Revenue
Q2Q % growth
EBITDA
Q2Q % growth		N/AN/A
EBIT
Q2Q % growth		-4.692M
8.29%		-4.547M
10.58%

All data in USD

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

BLPH Yearly Revenue VS EstimatesBLPH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2025 2026 2027 2028 2029 2030 100M 200M 300M 400M
BLPH Yearly EPS VS EstimatesBLPH Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -20 -40 -60

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year
39.61%
EPS Next 5 Year
22.86%

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

BELLEROPHON THERAPEUTICS INC / BLPH Forecast FAQ

What is the average price target for BELLEROPHON THERAPEUTICS INC (BLPH) stock?

6 analysts have analysed BLPH and the average price target is 2.04 USD. This implies a price increase of 1890.24% is expected in the next year compared to the current price of 0.1025.

Can you provide the upcoming earnings date for BELLEROPHON THERAPEUTICS INC?

BELLEROPHON THERAPEUTICS INC (BLPH) will report earnings on 2023-11-13, before the market open.

What are the consensus estimates for BELLEROPHON THERAPEUTICS INC (BLPH) next earnings?

The consensus EPS estimate for the next earnings of BELLEROPHON THERAPEUTICS INC (BLPH) is -0.45 USD and the consensus revenue estimate is 0 USD.

What is the consensus rating for BLPH stock?

The consensus rating for BELLEROPHON THERAPEUTICS INC (BLPH) is 43.3333 / 100 . This indicates that analysts generally have a neutral outlook on the stock.